Pfizer Bids For Swedish Maker of Treatment for NOMID

Is this a new employee for Pfizer? (Source: Muppet Wiki)

Looks like Pfizer wants to buy a Swedish company who provides a treatment for neonatal-onset multisystem inflammatory disease, (NOMID). NOMID belongs to a family of conditions known as Cryopyrin-Associated Periodic Syndromes, or CAPS. A mutation in the NLRP-3 gene is what causes CAPS.

According to Seeking Alpha contributor Douglas W. House, Sobi (Swedish Orphan Biovitrum), the company that makes interleukin-1 (IL-1) antagonist Kineret (anakinra), has a price tag of $4.3 billion. Kineret treats NOMID.

Surely the above picture doesn’t resemble their uniforms. But what else is Sobi cooking?  Read more…

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

What are your thoughts on being a rare disease advocate? Share your stories, thoughts, and hopes with the Patient Worthy community!

Close Menu